Phase I study of afatinib plus bevacizumab in patients with advanced non-squamous non-small cell lung cancer harboring EGFR mutations

Por Ko, Ryo, Shukuya, Takehito, Imamura, Chiyo K., Tokito, Takaaki, Shimada, Naoko, Koyama, Ryo, Yamada, Kazuhiko, Ishii, Hidenobu, Azuma, Koichi, Takahashi, Kazuhisa
Publicado no Transl Lung Cancer Res (2021)

Biology of invasive mucinous adenocarcinoma of the lung

Por Cha, Yoon Jin, Shim, Hyo Sup
Publicado no Transl Lung Cancer Res (2017)

Should sublobar resection be offered for screening-detected lung nodules?

Por Sihoe, Alan D. L.
Publicado no Transl Lung Cancer Res (2021)

Platelets and their role in cancer evolution and immune system

Por Karachaliou, Niki, Pilotto, Sara, Bria, Emilio, Rosell, Rafael
Publicado no Transl Lung Cancer Res (2015)

Afatinib in lung cancer harboring EGFR mutation in the LUX-Lung trials: six plus three is greater than seven?

Por Mitsudomi, Tetsuya, Kobayashi, Yoshihisa
Publicado no Transl Lung Cancer Res (2016)

Exploring controversies in lung cancer using structured pro-con debates

Por Senan, Suresh
Publicado no Transl Lung Cancer Res (2015)

Tumor cell proliferation, proliferative index and mitotic count in lung cancer

Por Chirieac, Lucian R.
Publicado no Transl Lung Cancer Res (2016)

Cons: should immunotherapy be incorporated in the treatment of oncogene-driven lung cancer?

Por Metro, Giulio, Di Maio, Massimo
Publicado no Transl Lung Cancer Res (2018)

PROS: should immunotherapy be incorporated in the treatment of oncogene-driven lung cancer?

Por Addeo, Alfredo, Banna, Giuseppe Luigi
Publicado no Transl Lung Cancer Res (2018)

PROS: should immunotherapy be incorporated in the treatment of oncogene-driven lung cancer?

Por Addeo, Alfredo, Banna, Giuseppe Luigi
Publicado no Transl Lung Cancer Res (2018)

Cons: should immunotherapy be incorporated in the treatment of oncogene-driven lung cancer?

Por Metro, Giulio, Di Maio, Massimo
Publicado no Transl Lung Cancer Res (2018)

Association between dietary sodium, potassium intake and lung cancer risk: evidence from...

Por You, Dongfang, Zhang, Mingzhi, He, Wenjing, Wang, Danhua, Yu, Yang, Yu, Zhaolei, Lange, Theis, Yang, Sheng, Wei, Yongyue, Ma, Hongxia, Hu, Zhibin, Shen, Hongbing, Chen, Feng, Zhao, Yang
Publicado no Transl Lung Cancer Res (2021)

Evaluation of the lung immune prognostic index in advanced non-small cell lung cancer patients under nivolumab monotherapy

Por Ruiz-Bañobre, Juan, Areses-Manrique, María C., Mosquera-Martínez, Joaquín, Cortegoso, Alexandra, Afonso-Afonso, Francisco J., de Dios-Álvarez, Noemí, Fernández-Núñez, Natalia, Azpitarte-Raposeiras, Cristina, Amenedo, Margarita, Santomé, Lucía, Fírvida-Pérez, José Luis, García-Campelo, Rosario, García-González, Jorge, Casal-Rubio, Joaquín, Vázquez, Sergio
Publicado no Transl Lung Cancer Res (2019)

Whole exome sequencing (WES) analysis of transformed small cell lung cancer (SCLC) from lung adenocarcinoma (LUAD)

Por Xie, Tongji, Li, Yan, Ying, Jianming, Cai, Weijing, Li, Junling, Lee, Kye Young, Ricciuti, Biagio, Pacheco, Jose, Xing, Puyuan
Publicado no Transl Lung Cancer Res (2020)

Stereotactic body radiotherapy for early stage non-small cell lung cancer in patients with subclinical interstitial lung disease

Por Liu, Yuanjun, Zhu, Yaoyao, Wu, Ran, Hu, Min, Zhang, Lingnan, Lin, Qingren, Weng, Denghu, Sun, Xiaojiang, Liu, Yu, Xu, Yaping
Publicado no Transl Lung Cancer Res (2020)

Translational Lung Cancer Research is endorsed by the Brazilian Society of Thoracic Surgery

Publicado no Transl Lung Cancer Res (2016)

The First Impact Factor for Translational Lung Cancer Research: 4.806

Publicado no Transl Lung Cancer Res (2019)

Application of the CARE guideline as reporting standard in the Translational Lung Cancer Research

Publicado no Transl Lung Cancer Res (2019)

Alectinib—a new chapter in the management of ALK-positive lung cancer

Por Gainor, Justin F.
Publicado no Transl Lung Cancer Res (2016)

Dr. Viola Zhu: is ethnicity a prognostic factor in lung cancer?

Por Liu, Macy
Publicado no Transl Lung Cancer Res (2017)